Resultados de la búsqueda

Tristão-Pereira C, Fuster V, Lopez-Jimenez A, Fernández-Pena A, Semerano A, Fernandez-Nueda I, Garcia-Lunar I, Ayuso C, Sanchez-Gonzalez J, Ibanez B, Gispert JD, Cortes-Canteli M. Subclinical atherosclerosis and brain health in midlife: Rationale and design of the PESA-Brain study. Am Heart J (2024) 278:195-207
Link to the full text in Repisalud

Lamanna-Rama N, Romero-Miguel D, Casquero-Veiga M, MacDowell KS, Santa-Marta C, Torres-Sánchez S, Berrocoso E, Leza JC, Desco M, Soto-Montenegro ML. THC improves behavioural schizophrenia-like deficits that CBD fails to overcome: a comprehensive multilevel approach using the Poly I:C maternal immune activation. PSYCHIAT RES (2024) 331:115643

Domingo-Gardeta T, Montero-Cabezas JM, Jurado-Román A, Sabaté M, Aboal J, Baranchuk A, Carrillo X, García-Zamora S, Dores H, van der Valk V, Scherptong RWC, Andrés-Cordón JF, Vidal P, Moreno-Martínez D, Toribio-Fernández R, Lillo-Castellano JM, Cruz R, De Guio F, Marina-Breysse M, Martínez-Sellés M. Rationale and design of the artificial intelligence scalable solution for acute myocardial infarction (ASSIST) study. J Electrocardiol (2024) 86:153768

Romero-Miguel D, Casquero-Veiga M, Lamanna-Rama N, Torres-Sánchez S, MacDowell KS, García-Partida JA, Santa-Marta C, Berrocoso E, Leza JC, Desco M, Soto-Montenegro ML. N-acetylcysteine during critical neurodevelopmental periods prevents behavioral and neurochemical deficits in the Poly I:C rat model of schizophrenia Transl Psychiatry (2024) 14:14
Link to the full text in Repisalud

Aguzzoli Peres F, Haas AN, Martha AD, Chan M, Steele M, Ferretti MT, Ngcobo NN, Ilinca S, Domínguez-Vivero C, Leroi I, Sajnani N, Zimmer ER, Kornhuber A, Kalache A, Holtzhausen B, Tristão-Pereira C, Dupont C, Cohen D, de Jong D, Facal D, O'Sullivan D, Mateus E, Roso E, Estrop E, Gamba G, San Martin Elexpe G, Ulises Diaz Hernández H, Quaid H, Govia I, Barbosa J, García Del Moral J, Miller J, García García JA, Quaid K, Navarro L, García LZ, Waters L, Molete L, Godoy ME, Sigauke M, de Ataide Schulte MW, Estrop P, San Martin Elexpe Cardoso P, Perez R, Patterson R, Chakrabarti R, Wong R, Marsillas S, Lowe S, Rego TS, Farombi T, Montgomery T, In 't Veen T, Yanni V, Weidner W, Ibanez A. Walking the talk for dementia: A unique immersive, embodied, and multi-experiential initiative. Alzheimers Dement (2024) 20:2309-2322
Link to the full text in Repisalud

Santos-Beneit G, Fernández-Jiménez R, Fuster V. Education and Information to Improve Cardiovascular Health-Reply. JAMA Cardiol (2024) 9:306-307

Goldman SA, Requena-Ibanez JA, Devesa A, Santos-Gallego CG, Badimon JJ, Fuster V. Uncovering the Role of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction. JACC Adv (2024) 2:100657.

Fiolet ATL, Poorthuis MHF, Opstal TSJ, Amarenco P, Boczar KE, Buysschaert I, Budgeon C, Chan NC, Cornel JH, Jolly SS, Layland J, Lemmens R, Mewton N, Nidorf SM, Pascual-Figal DA, Price C, Shah B, Tardif JC, Thompson PL, Tijssen JGP, Tsivgoulis G, Walsh C, Wang Y, Weimar C, Eikelboom JW, Mosterd A, Kelly PJ; Colchicine Cardiovascular Trialists Collaboration. Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials. EClinicalMedicine (2024) 76:102835
Link to the full text in Repisalud

Pascual-Figal D, Bayes-Genis A. Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review. Front Cardiovasc Med (2024) 11:1439696
Link to the full text in Repisalud

Bayes-Genis A, Pascual-Figal D. Making STRONGer the transition phase: personalized GDMT through NT-proBNP monitoring. Eur Heart J (2023) 44:2963-2965.
Link to the full text in Repisalud